Page 115 - 《中国药房》2025年3期

patients with therapy-refractory advanced colorectal cancer [30] ABDULBAQI I M，ASSI R A，YAGHMUR A，et al. Pul‐
[J]. Cancer Chemother Pharmacol，2006，58（6）：759-764. monary delivery of anticancer drugs via lipid-based nano‐
[18] DNEWMAN M S，COLBERN G T，WORKING P K， carriers for the treatment of lung cancer：an update[J].
et al. Comparative pharmacokinetics，tissue distribution， Pharmaceuticals （Basel），2021，14（8）：725.
and therapeutic effectiveness of cisplatin encapsulated in [31] CHOU A J，GUPTA R，BELL M D，et al. Inhaled lipid cis‐
long-circulating，pegylated liposomes （SPI-077） in tumor- platin （ILC） in the treatment of patients with relapsed/pro‐
bearing mice[J]. Cancer Chemother Pharmacol，1999，43 gressive osteosarcoma metastatic to the lung[J]. Pediatr
（1）：1-7. Blood Cancer，2013，60（4）：580-586.
[19] MEERUM TERWOGT J M，GROENEWEGEN G， [32] LANCET J E，UY G L，NEWELL L F，et al. CPX-351
PLUIM D，et al. Phase Ⅰ and pharmacokinetic study of versus 7+3 cytarabine and daunorubicin chemotherapy in
SPI-77，a liposomal encapsulated dosage form of cisplatin older adults with newly diagnosed high-risk or secondary
[J]. Cancer Chemother Pharmacol，2002，49（3）：201-210. acute myeloid leukaemia：5-year results of a randomised，
[20] SEETHARAMU N，KIM E，HOCHSTER H，et al. Phase open-label，multicentre，phase 3 trial[J]. Lancet Haematol，
Ⅱ study of liposomal cisplatin （SPI-77） in platinum- 2021，8（7）：e481-e491.
sensitive recurrences of ovarian cancer[J]. Anticancer Res， [33] JANSE VAN RENSBURG H D，SUGANUMA K，N’DA
2010，30（2）：541-545. D D. In vitro trypanocidal activities and structure-activity
[21] FAROOQ M A，AQUIB M，FAROOQ A，et al. Recent relationships of ciprofloxacin analogs[J]. Mol Divers，
progress in nanotechnology-based novel drug delivery sys‐ 2024，28（4）：2667-2680.
tems in designing of cisplatin for cancer therapy：an over‐ [34] CAI X Z，SHI S，CHEN G，et al. Glutamine metabolism
targeting liposomes for synergistic chemosensitization and
view[J]. Artif Cells Nanomed Biotechnol，2019，47（1）：
1674-1692. starvation therapy in ovarian cancer[J]. Acta Biomater，
2023，158：560-570.
[22] STATHOPOULOS G P，BOULIKAS T. Lipoplatin formu‐
lation review article[J]. J Drug Deliv，2012，2012：581363. [35] WANG S H，GOU J X，WANG Y，et al. Synergistic antitu‐
mor efficacy mediated by liposomal co-delivery of poly‐
[23] XU B，ZENG M，ZENG J W，et al. Meta-analysis of clini‐
meric micelles of vinorelbine and cisplatin in non-small
cal trials comparing the efficacy and safety of liposomal
cisplatin versus conventional nonliposomal cisplatin in cell lung cancer[J]. Int J Nanomedicine，2021，16：2357-
2372.
nonsmall cell lung cancer （NSCLC） and squamous cell
carcinoma of the head and neck （SCCHN）[J]. Medicine [36] SHAH H，MADNI A，KHAN M M，et al. PH-responsive
liposomes of dioleoyl phosphatidylethanolamine and cho‐
（Baltimore），2018，97（46）：e13169.
[24] ZOU J Y. Site-specific delivery of cisplatin and paclitaxel lesteryl hemisuccinate for the enhanced anticancer effi‐
cacy of cisplatin[J]. Pharmaceutics，2022，14（1）：129.
mediated by liposomes：a promising approach in cancer
[37] CHEN J Y，HU S Y，SUN M，et al. Recent advances and
chemotherapy[J]. Environ Res，2023，238（Pt 1）：117111. clinical translation of liposomal delivery systems in can‐
[25] DE JONGE M J A，SLINGERLAND M，LOOS W J，et al.
cer therapy[J]. Eur J Pharm Sci，2024，193：106688.
Early cessation of the clinical development of LiPlaCis，a
[38] YANG Y Y，LIU X，MA W，et al. Light-activatable lipo‐
liposomal cisplatin formulation[J]. Eur J Cancer，2010，46
somes for repetitive on-demand drug release and immuno‐
（16）：3016-3021.
potentiation in hypoxic tumor therapy[J]. Biomaterials，
[26] PENG S Y，WANG W H，ZHANG R，et al. Nano- 2021，265：120456.
formulations for pulmonary delivery：past，present，and fu‐
[39] GUTIERREZ-ROMERO L，DÍEZ P，MONTES-BAYÓN
ture perspectives[J]. Pharmaceutics，2024，16（2）：161. M. Bioanalytical strategies to evaluate cisplatin nanodeli-
[27] TAGHAVIZADEH YAZDI M E，QAYOOMIAN M，
very systems：from synthesis to incorporation in indi‐
BEIGOLI S，et al. Recent advances in nanoparticle appli‐ vidual cells and biological response[J]. J Pharm Biomed
cations in respiratory disorders：a review[J]. Front Pharma‐
Anal，2024，237：115760.
col，2023，14：1059343. [40] PATEL K D，DE ZOYSA G H，KANAMALA M，et al.
[28] WITTGEN B P H，KUNST P W A，VAN DER BORN K， Novel cell-penetrating peptide conjugated proteasome in‐
et al. Phase Ⅰ study of aerosolized SLIT cisplatin in the hibitors：anticancer and antifungal investigations[J]. J Med
treatment of patients with carcinoma of the lung[J]. Clin Chem，2020，63（1）：334-348.
Cancer Res，2007，13（8）：2414-2421. [41] BIAN X F，GUO T，CHEN G J，et al. The therapeutic ef‐
[29] KOSHKINA N V，KNIGHT V，GILBERT B E，et al. Im‐ fect and MR molecular imaging of FA-PEG-FePt/DDP
proved respiratory delivery of the anticancer drugs，camp‐ nanoliposomes in AMF on ovarian cancer[J]. Int J Nano‐
tothecin and paclitaxel，with 5% CO2-enriched air：pharma‐ medicine，2024，19：5227-5243.
cokinetic studies[J]. Cancer Chemother Pharmacol，2001， （收稿日期：2024-07-19 修回日期：2024-12-02）
47（5）：451-456. （编辑：胡晓霖）

中国药房 2025年第36卷第3期 China Pharmacy 2025 Vol. 36 No. 3 · 361 ·